Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chattem pHisoderm Clear Swab Launch Will Target “Back-To-School” Crowd

This article was originally published in The Tan Sheet

Executive Summary

Chattem will back the launch of pHisoderm Clear Swab with dedicated ads and product sampling
Advertisement

Related Content

Icy Hot Back Pain Patch Sales Could Reach $6 Mil.-$8 Mil., Chattem Says
Chattem Gold Bond Bolstered With Three New Products Shipping In 2003
Playtex Heat Therapy Patches Slated For Feminine Care Aisle Positioning
Chattem Acquisition Fund Expected To Reach $40 Mil. With Offering
Chattem Advertising Strategy Relies On “Guerrilla” Tactics – CEO Guerry
Chattem Selsun Blue Purchase Provides Entry Into Five New Foreign Markets
Chattem Eyes International Growth, Doubling Of Net Sales
Pfizer Consumer Health Is “Logical Extension” Of Rx – CEO McKinnell
Chattem Dexatrim Results To Reduce Weight-Loss Side Effects, Firm Says
Chattem Dexatrim Results To Reduce Weight-Loss Side Effects, Firm Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS093817

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel